Harvest Fund Management Co. Ltd Reduces Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Harvest Fund Management Co. Ltd trimmed its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 27,125 shares of the company’s stock after selling 615 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in GE HealthCare Technologies were worth $2,105,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new stake in shares of GE HealthCare Technologies during the 3rd quarter valued at $31,000. Continuum Advisory LLC raised its stake in shares of GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the period. Bank of Jackson Hole Trust bought a new stake in shares of GE HealthCare Technologies during the 4th quarter valued at $32,000. Flagship Wealth Advisors LLC bought a new stake in shares of GE HealthCare Technologies during the 4th quarter valued at $34,000. Finally, OFI Invest Asset Management bought a new stake in shares of GE HealthCare Technologies during the 4th quarter valued at $34,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on GEHC. Wells Fargo & Company boosted their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their target price for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. Citigroup upped their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their target price for the stock from $85.00 to $100.00 in a research note on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $98.75.

GE HealthCare Technologies Trading Up 0.3 %

Shares of GEHC stock opened at $82.40 on Thursday. The stock has a market capitalization of $37.68 billion, a PE ratio of 19.03, a P/E/G ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80. The business has a 50-day moving average of $87.17 and a 200 day moving average of $86.08. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.19. The company had revenue of $5.32 billion during the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. As a group, sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.